Royalty Report: Drugs, Biotechnology, Therapeutic – Collection: 28366

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 12

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 12

Primary Industries

  • Drugs
  • Biotechnology
  • Therapeutic
  • Agriculture
  • Forestry and Fishing
  • cardiac
  • Molecular
  • Proteins
  • Silk
  • Diagnostic
  • Cancer
  • Stem cells
  • Antibody
  • Disease
  • Drug Discovery
  • Immune

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 28366

License Grant
Sublicensor hereby grants to Sublicensee and Sublicensee hereby accepts a non-exclusive, non-transferable sublicense under the 4,873,191 Patent to use the Patented Technology during the term of this Agreement as described in the Field of Use, without the right to grant further sublicenses except to Affiliates of Sublicensee.
License Property
United States Letters Patent No. 4,873,191 pertaining to a method of obtaining genetic transformation of a zygote and the embryo and mature organism.

'Transgenic Animal' shall mean any non-human mammal developed by, through or with the use of the Patented Technology, including, without limitation, any descendent of such mammal which has inherited genetic material which was originally transferred to an ancestor by use of the Patented Technology, and any zygotes or embryos, or cells or tissues of or derived from such mammal or descendent.

'Transgenic Production System' shall mean a Transgenic Animal which is used to produce at a commercial scale a product that is recovered from the Transgenic Animal, or any cells, tissue, or fluid of or derived from the Transgenic Animal (including, without limitation, its milk, mammary cells and tissue, urine, or hematopoetic cells, tissues, and fluids) whether or not recovery and use of the product in commerce involves or requires further processing, culturing, purification, manipulation, formulation, or other such steps.

'Production Genetic Material' shall mean genetic material which is designed and engineered in a manner such that when introduced into and expressed in a mammal results in a Transgenic Animal that can reasonably be employed as a Transgenic Production System.

Field of Use
The Field of Use relates to (i) Development of Transgenic Mammary Production Systems Sublicensee may use the Patented Technology to transfer Mammary Production Genetic Material to develop Transgenic Mammary Production Systems and may use, sell or otherwise commercially exploit the Transgenic Mammary Production Systems thereby developed, but only insofar as the Transgenic Mammary Production Systems are to be used for the purpose of making Transgenic Mammary Products; and (ii) Development of Transgenic Experimental Animals Sublicensee may use the Patented Technology under this Agreement to develop Transgenic Experimental Animals (except Transomic Animals or Transgenic Production Systems) for use by Sublicensee, and only Sublicensee, in testing or evaluating products which are manufactured or being developed by Sublicensee, but Sublicensee is not sublicensed to sell, lease, rent, barter away or otherwise transfer Transgenic Experimental Animals so developed.

IPSCIO Record ID: 289146

License Grant
The Netherlands Licensor hereby grants Licensee and its Affiliates a non-exclusive, worldwide, non-terminable license with the right to grant sublicenses, under the Licensor Patent Rights for all uses in the Field, including without limitation, to make, have made, use, sell, offer for sale, import and export Licensee Licensed Products in the Field. Such license shall not expire until the last to expire Valid Claim of the Licensor Patent Rights.
License Property
Licensor Patent Rights shall mean (a) all patents and patent applications as set forth hereto and incorporated herein, together with any and all patents that have issued or in the case of applications heretofore filed, in the future issue therefrom or whose priority date is based thereon; and (b) all related divisionals, continuations, continuations-in-part, national stage applications or patents filed under the Patent Cooperation Treaty of 1978, reissues, renewals, extensions or additions to any such patents and patent applications; but shall specifically exclude the Biogen Patent Rights and the ProBio Patent Rights.
5,304,489 – DNA sequences to target proteins to the mammary gland for efficient secretion
5,565,362 – DNA sequences to target proteins to the mammary gland for efficient secretion
5,633,076 – Method of producing a transgenic bovine or transgenic bovine embryo

Licensee Licensed Product shall mean any product, the manufacture, use, or sale of which would, absent the licenses granted to Licensee hereunder, infringe one or more Valid Claims of the Licensor Patent Rights.

Biopharmaceutical shall mean any medicinal drug, therapeutic, vaccine or any medically useful composition whose origin, synthesis, or manufacture involves the use of microorganisms, recombinant animals (including, without limitation, chimeric or transgenic animals), nuclear transfer, microinjection, or cell culture techniques.

HSA shall mean human serum albumin.

Field of Use
Field shall mean (a) the Cattle Field; (b) the Goat Field; (c) the production, use and/or sale of transgenic or chimeric mice, rabbits, pigs, and/or sheep (including their respective embryos, gametes and/or progeny) for the production of Biopharmaceuticals in the milk (including any fraction thereof) secreted from such transgenic or chimeric animals; and (d) the use in any transgenic or chimeric cattle, goats, mice, rabbits, pigs, and/or sheep of a nucleic acid construct useful in the production of a system that includes the use of a recombinant casein promoter sequence, which permits a female transgenic or chimeric animal to produce a desired Biopharmaceutical in the milk (or any fraction thereof) of such a transgenic or chimeric cattle, goats, mice, rabbits, pigs, and/or sheep during lactation.

Goat Field shall mean the production, use and/or sale of transgenic or chimeric goats (including their respective embryos, gametes and/or progeny) for the production of Biopharmaceuticals in the milk (including any fraction thereof) secreted from such transgenic or chimeric goats.

Cattle Field shall mean the production, use and/or sale of transgenic or chimeric cattle (including their respective embryos, gametes and/or progeny) for the production of Biopharmaceuticals in the milk (including any fraction thereof) secreted from such transgenic or chimeric cattle, including, without limitation, the production of hSA.

IPSCIO Record ID: 28404

License Grant
Licensor hereby grants to Licensee, and Licensee hereby accepts, subject to the terms and conditions hereof a) A royalty bearing, exclusive license in the Territory in the Field and under the Licensed Technology to (a) research, develop, make, have made, use, sell, offer for sale, import and export Licensed Products, (b) research, develop, use, practice, sell, offer for sale, import and export Licensed Processes and (c) develop, use, perform, sell, offer for sale, import and export Licensed Services.

By way of example, but not in limitation, Licensee shall have the right to use Licensed Technology within the Field for the following purposes to produce mammalian embryonic stem (ES) cells and to produce from those mammalian embryonic cells, differentiated cells for human therapeutic purposes or for commercial research purposes, including drug screening assays, and to produce pluripotent cells including ES cells, differentiated human cells for human diagnostic and therapeutic purposes and/or for commercial research purposes, including drug screening assays. b) A royalty bearing, twelve (12) month exclusive license in the Territory in the Field to expand in culture, prepare for sale, sell, offer for sale, import and export Act Animal Cell Lines. The twelve-month term of exclusivity granted to Licensee shall begin upon the date of the first sale of the Act Animal Cell Lines. Licensor and Licensee agree that after the twelve-month period of exclusivity has passed, Licensor and Licensee shall negotiate in good faith to establish reasonable minimum sales goals over reasonable evaluation periods in order to maintain Licensee’s exclusive rights hereunder. If Licensor fails to meet the minimum sales goals then Licensee’s exclusive rights shall revert to nonexclusive rights.

License Property
“Act Animal Cell Lines” shall mean cell lines of non-human animal origin developed by Act. These cell lines shall include but not be limited to murine and primate embryonic stem cells derived through parthenogenesis, nuclear transfer or otherwise isolated from fertilized blastocysts including the relevant information Licensor possesses associated with these cells, including but not limited to information on the cell’s karyotype, gene expression and growth characteristics.

PATENT RIGHTS
08/935,052  US 1997-09-22 CICM Cells and Non-Human Mammalian Embryos

6,235,970 2001-05-22  Prepared by Nuclear Transfer of a Proliferating Differentiated Cell or its Nucleus

09/828,876 US 2001-04-10 Cloning Using Donor Nuclei from Differentiated Fetal and Adult Cells UMASS

10/374,512 US 2003-02-27 Gynogenetic or Androgenetic Production of Pluripotent Cells and Cell Lines, and Use Thereof to Produce Differentiated Cells and Tissues

60/161,987 US 1999-10-28 Gynogenetic or Androgenetic Production of Pluripotent Cells and Cell Lines, and Use Thereof to Produce Differentiated Cells and Tissues

2,387,506 CA 2000-10-27 Gynogenetic or Androgenetic Production of Pluripotent Cells and Cell Lines, and Use Thereof to Produce Differentiated Cells and Tissues

Declared patent interferences
a) Patent Interference No. 104,746, involving U.S. Patent No. 5,945,577 and U.S. Patent Application No. 09/650,194.

b) Patent Interference No. 105,192, involving U.S. Patent No. 6,235,970 and U.S. Patent Application No. 09/989,126.

Potential patent interferences, verbally threatened to be filed against the following patents
a) 6,215,041

b) 6,235,969

Field of Use
“Field” shall mean (1) the research, development, manufacture and selling of human and non-human animal cells and Act Animal Cell Lines for commercial research use, including small molecule and other drug testing and basic research, (2) the manufacture and selling of human cells for therapeutic and diagnostic use in the treatment of human (a) diabetes and (b) liver diseases, and (3) the use of Act Animal Cell Lines in the process of manufacturing and selling human cells for therapeutic and diagnostic use in the treatment of human (a) diabetes and (b) liver diseases but where the final marketed product does not include Act Animal Cell Lines (i.e. does not include the field of xenotransplantation); but Field shall exclude applications involving the use of cells in the treatment of tumors where the primary use of the cells is the destruction or reduction of tumors and does not involve regeneration of tissue or organ function.

IPSCIO Record ID: 290208

License Grant
Licensor hereby grants Netherlands Licensee and its Affiliates a non-exclusive, worldwide, non-terminable license with the right to grant sublicenses, under the Licensor Patent Rights (other than the Licensor Antibody Patent Rights), for all uses in the Field, including, without limitation, to make, have made, use, sell, offer for sale, import and export Licensee Licensed Products in the Field. Such license shall not expire until the earlier of (i) the expiration of the last to expire Valid Claim of the Licensor Patent Rights other than the Licensor Antibody Patent Rights or (ii) termination of this Agreement of this Agreement.
License Property
Licensor Patent Rights shall mean (a) USSN 07/938,322 entitled 'Transgenic Animals Secreting Desired Proteins into Milk', including, without limitation, EP-973031124, and any foreign counterpart applications, together with any and all patents that have issued or in the case of applications heretofore filed, in the future issue therefrom or whose priority date is based thereon; and (b) all related divisionals,  continuations, national stage applications or patents filed under the Patent Cooperation Treaty of 1978, reissues or renewals, of the foregoing; and (c) the Licensor Antibody Patent Rights.

Licensor Antibody Patent Rights shall mean (a) U.S. Patent Nos. 5,827,690 and 5,849,992 both entitled 'Transgenic Production of Antibodies in Milk', and all U.S. patent applications and any foreign counterpart applications, and future issued patents including all patents that have issued or in the case of applications heretofore filed, in the future issue therefrom or whose priority date is based thereon; and all related divisionals, continuations, national stage applications or patents filed under the Patent Cooperation Treaty of 1978, reissues or renewals, of the foregoing pertaining to the production of antibodies in the milk of transgenic mammals.

Biopharmaceutical shall mean any medicinal drug, therapeutic, vaccine or any medically useful composition whose origin, synthesis, or manufacture involves the use of microorganisms, recombinant animals (including, without limitation, chimeric or transgenic animals), nuclear transfer, microinjection, or cell culture techniques.

HSA shall mean human serum albumin.

Field of Use
Field shall mean (a) the Cattle Field; (b) the Goat Field; (c) the production, use and/or sale of transgenic or chimeric mice, rabbits, pigs, and/or sheep (including their respective embryos, gametes and/or progeny) for the production of Biopharmaceuticals in the milk (including any fraction thereof) secreted from such transgenic or chimeric animals; and (d) the use in any transgenic or chimeric cattle, goats, mice, rabbits, pigs, and/or sheep of a nucleic acid construct useful in the production of a system that includes the use of a recombinant casein promoter sequence, which permits a female transgenic or chimeric animal to produce a desired Biopharmaceutical in the milk (or any fraction thereof) of such a transgenic or chimeric cattle, goats, mice, rabbits, pigs, and/or sheep
during lactation.

Goat Field shall mean the production, use and/or sale of transgenic or chimeric goats (including their respective embryos, gametes and/or progeny) for the production of Biopharmaceuticals in the milk (including any fraction thereof) secreted from such transgenic or chimeric goats.

Cattle Field shall mean the production, use and/or sale of transgenic or chimeric cattle (including their respective embryos, gametes and/or progeny) for the production of Biopharmaceuticals in the milk (including any fraction thereof) secreted from such transgenic or chimeric cattle, including, without limitation, the production of hSA.

IPSCIO Record ID: 238999

License Grant
For the Licensor Platform Rights,  Licensor grants to an exclusive worldwide, license, with the right to grant sublicenses, under the Licensor Platform Rights, Licensed Improvements and Licensors rights in the Joint Platform Improvements to make, have made, use, sell, offer for sale, import and export Licensed Products in the Field.

For the Cattle Rights, Licensor grants a non-exclusive, worldwide license, with the right to grant sublicenses, under the Cattle Patent Rights to make, have made, use, sell, offer for sale, import and export Cattle Products in the Field.

For the Promoter Rights, Licensor grants a non-exclusive, worldwide license, without the right to grant sublicenses, under the Promoter Rights to make, have made, use and sell Promoter Products in the Field.

License Property
The Licensor has substantial programs and interest in the development of transgenic animals for the production of proteins, peptides and polypeptides in the milk of such animals for use as Biopharmaceuticals.

The licensed patents are for Cattle Patent Rights, Platform Patent Rights, rhSA Patent Rights, and, Promoter Patent Rights.

Recombinant Human Serum Albumin (rhSA) is a plasma protein that is principally responsible for maintaining the osmotic pressure in the vascular system, as well as plasma volume and the balance of fluids in blood.

Field of Use
Field shall mean the development, manufacture, use, marketing, sale and overall commercialization of rhSA or any Biopharmaceutical derived from or utilizing rhSA (but excluding fusion proteins) for therapeutic and non-therapeutic uses.

IPSCIO Record ID: 28106

License Grant
The Canadian University grants the Licensee an exclusive license under the Improvement Patents and Project Intellectual Property in the Field of Use to create transgenic silkworms for the production of recombinant silk fibers.
The Licensor grants the Licensee a non-exclusive license under the Parent Patents in the Field of Use.
The Licensor grants the Licensee a right to use, and commercially exploit, the Background Intellectual Property and/or Project Intellectual Property in the Field of Use.
License Property
The Licensor has patents in the field of chimeric Spider Silk and their uses and has developed various technologies related to piggyBac transposons and genetic transformation systems for producing transgenic organisms.
Field of Use
The Licensee is a developer of advanced spider silk based fibers.

IPSCIO Record ID: 274943

License Grant
Licensor hereby grants Licensee a worldwide, royalty-bearing, non-terminable, non-exclusive license under the Licensor Technology and Licensor Patents to make, have made, use, and sell Licensee Products in the Licensee Field. Such license will not expire until the expiration of the last to expire valid claim of the Licensor Patents.
License Property
Patents
5,304,489 – DNA sequences to target proteins to the mammary gland for efficient secretion
US 4,837,316 – Alkylamide derivatives with H.sub.2 -receptor antagonistic and cytoprotective action
US 5,750,172 – Transgenic non human mammal milk

Licensor Technology shall mean the materials owned or controlled by Licensor which are useful in the Licensee Field and which are listed
Casein Expression system
Human Serum Albumin
Basic Research Tools

Field of Use
Licensee Field shall mean the production of any protein in the milk of any transgenic animal, except the commercial production of urokinase in the milk of any animal and the commercial production of alpha-amalyse, alpha-lactalbumin, desaturase, lactase, lactoferrin, lactoperoxidase, lysozyme and bile-salt stimulated lipase in the milk of cattle. In addition, Licensee agrees it will not commercially produce Factor VIII in the milk of any animal without first obtaining the written permission of Licensor.

IPSCIO Record ID: 6970

License Grant
Licensor hereby grants to Licensee and its Affiliates a royalty-bearing, exclusive (even as to Licensor, except for the retained rights described in Section 2.1(b) below), transferable (solely in accordance with Section 11.1), sublicensable (solely in accordance with Section 2.2) license or sublicense, as the case may be, under its rights in the Patent Rights and Technology, to develop, make, have made, use, sell, have sold, offer to sell, import, export, reproduce, distribute, perform and display, and otherwise dispose of Licensed Products, and to develop and perform Licensed Services, and to use and practice in products and services any process, art or method, included in the Licensor Technology, in the Territory in the Field of Use. This Agreement is subject to the relevant terms of the Brandeis License applicable to sublicensees as such terms have been incorporated herein, as the Brandeis License may be amended from time to time, provided, that (i) as provided in Section 2.1(c) below, the Brandeis License may not be amended in a manner that materially and adversely affects the rights and benefits extended to Licensee hereunder without the prior written consent of Licensee, and (ii) in the event of any inconsistency between the Brandeis License and Section 2.1(c) hereof, Section 2.1(c) hereof shall govern.
License Property
Patent Rights
U.S. Patents – 5,480,772; 5,651,992; 5,773,217; 6,245,567; 6,753,457; 6,878,546.
U.S. Patent Applications – 10/798,061; 10/969,646.
Foreign Patent Applications – WO9418344; EP154931; EP0686202; CA2155309.
Field of Use
Field of Use means
(a)  non-human cells, embryos, organs, organisms;
(b)  any of (a) above as cloned, transgenic, or cloned transgenic forms;
(c)  any protein products and other biological molecules produced by, or prepared from, (a) and (b) above;
(d)  any methods, technologies, or processes for the creation of (a) through (c) above;
(e)  therapeutic and diagnostics (including products, devices, or processes) of (a) through (d) above;
(f)  cloned, transgenic, or cloned transgenic human cells, tissues and organs not derived by Human Cloning (as defined below).

The Field of Use shall under no circumstances include
(i)  the use of Human Reproductive Cells (Human Reproductive Cells are defined herein as human meiotic or post-meiotic germ cells, human gametes, human fertilized eggs, or human pre-implantation embryos) for any purpose;
(ii)  Human Cloning (wherein Human Cloning is defined as any action combining a human egg or any part thereof, with the nucleus or any nuclear material from any human cell);
(iii)  human embryos, cloned embryos, human tissue derived by Human Cloning; or
(iv)  transgenic human embryos, transgenic cloned human embryos, transgenic human cells, or transgenic human tissues derived by Human Cloning.

IPSCIO Record ID: 26263

License Grant
Licensor hereby grants to Licensee, a royalty bearing, exclusive, worldwide License in the Field of  research, development, manufacture and selling of human cells for cell therapy in the treatment of human diabetes and liver diseases.
License Property
The Technology is to research, develop, make, have made, use, sell, offer for sale, import and export Licensed Products, Processes and Services to produce human embryonic stem cells and to produce from those mammalian embryonic cells, differentiated cells for human cell therapy within the Field, and to produce pluripotent cells including ES cells, differentiated human cells for cell therapy within the field.

5,453,366 Method of Cloning Bovine Embryos

6,011,197 Method of Cloning Bovines Using Reprogrammed Non-mbryonic Bovine Cells

6,258,998 Method of Cloning Porcine Animals

5,843,754 Parthenogenic Bovine Oocyte Activation

5,496,720 Parthenogenic Oocyte Activation

09/573,044 Use of embryonic stem cells as nuclear donors during nuclear transfer and use of said techniques to produce chimeric and transgenic animals.

6,194,202 Parthenogenic Oocyte Activation

6,077,710  Parthenogenic Oocyte Activation

6,107,543  Culture of Totipotent Embryonic Inner Cells Mass Cells and Production of Bovine
Animals

Field of Use
The Field shall exclude applications involving the use of cells in the treatment of tumors where the primary use of the cells is the destruction or reduction of tumors and does not involve regeneration of tissue or organ function.

IPSCIO Record ID: 28341

License Grant
The Australian Licensor grants to the US Licensee a world-wide sole and exclusive right and license, including the right to sub-license third parties, of the Licensed rights to make, have made, use and sell or have sold on its behalf product.
License Property
The product material shall mean any material or substance in the possession of Licensor, including but not limited to any natural progeny of swine or progeny developed from swine by Licensor using any techniques of genetic engineering, including but not limited to transgenic technology, nuclear transfer, gene knockout and transfer of inner cell mass and any products derived from swine, including but not limited to proteins, cell lines, oocyte, spermatozoa, embryo or fetus thereof.
Field of Use
The field is defined as products and processes useful in xenotransplantation in humans, including but not limited to transplantation of cells, organs and tissues and/or products and processes useful for researching, developing, manufacturing, using or selling of products and processes for xenotransplantation in humans.

IPSCIO Record ID: 222550

License Grant
Licensee desires Licensor to conduct research with the Mice to generate fully human monoclonal antibodies to certain Antigens.

For the Evaluation License, Licensor grants an exclusive, nontransferable license for the term of the applicable Evaluation Period to use the Collaboration Technology relating to such Antigen solely for the purpose of evaluating whether Licensee shall desire to acquire a commercial license to such Product(s) directed against such Antigen.

For the Option for Commercial Licenses, Licensee shall have an option to obtain a commercial license with respect to Product(s) directed against such Antigen in the Field of Use in all countries of the Territory,

For the Commercial License,  Licensor grants an exclusive, even as to Licensor, license, with the right to sublicense, under the Licensed Technology to make, have made, import, have imported, use, offer for sale and sell Product(s) directed against such Antigen in the Field of Use in the Territory.

For the Research License, Licensee shall have an irrevocable, perpetual, worldwide exclusive research license, without the right to sublicense, to make and use (but not to transfer, sell, lease, offer to sell or lease, or otherwise transfer title to or interest in the Antibody{ies) and Antibody Cell(s) transferred by Licensor to Licensee, and any related Collaboration Technology, including Genetic Material(s) relating specifically and solely to such Antibody(ies) and Antibody Cell(s), in each case, and an irrevocable, perpetual, worldwide non-exclusive research license, without the right to sublicense, to make and use, but not to transfer, sell, lease, offer to sell or lease, or otherwise transfer title to or interest in the Collaboration Technology relating specifically and solely to antibody(ies), antibody cell(s) or genetic material(s) having a binding specificity and affinity for such Antigen, in each case, which is necessary for Licensee to make and use the same for research.

License Property
The patents relate to Transgenic non-human animals capable of producing heterologous antibodies.

The Collaboration Know How shall mean, with respect to each Antigen, any parts or derivatives of the Mice prepared by Licensor in connection with the applicable Immunization and delivered to Licensee, including without limitation, Antibody(ies), Antibody Cell(s), polypeptides, Genetic Material(s) or other biological materials derived directly or indirectly from the Mice delivered to Licensee, all information relating specifically and solely to the foregoing, including without limitation, technical data, protocols and methods and processes with respect to Product(s) directed against such Antigen and, all information relating specifically and solely to antibody(ies), antibody cell(s) or genetic material(s) having a binding specificity and affinity for such Antigen, including without limitation, technical data, protocols and methods and processes.

Product(s) shall mean, with respect to an Antigen, a composition or compositions with each composition comprising one or more Antibody(ies), Antibody Cell(s) or Genetic Material(s).

Licensor is the sole and exclusive owner of certain transgenic Mice useful for the preparation of fully human monoclonal antibodies.

HuMAb -Mouse technology is a transgenic mouse system that creates high-affinity, fully human antibodies instead of mouse antibodies.  Using standard, well proven laboratory techniques, scientists can produce these antibodies in a matter of months.

Bispecific antibodies, which enhance and direct the body's own immune system to fight disease; and immunotoxin  technology.

Field of Use
The Field of Use shall mean all uses of Product(s), including all human therapeutic, prophylactic and diagnostic uses of Product(s).

IPSCIO Record ID: 28403

License Grant
Licensor hereby grants to Licensee, and Licensee hereby accepts, subject to the terms and conditions hereof, a royalty bearing, exclusive license in the Territory in the Field and under the Licensed Technology to (a) research, develop, make, have made, use, sell, offer for sale, import and export Licensed Products, (b) research, develop, use, practice, sell, offer for sale, import and export Licensed Processes and (c) develop, use, perform, sell, offer for sale, import and export Licensed Services. By way of example, but not in limitation, Licensee shall have the right to use Licensed Technology within the Field to produce mammalian embryonic stem (ES) cells and to produce from those mammalian embryonic cells, differentiated cells for human therapeutic purposes or for commercial research purposes, including drug screening assays, and to produce pluripotent cells including ES cells, differentiated human cells for human diagnostic and therapeutic purposes and/or for commercial research purposes, including drug screening assays.
License Property
60/382,616 Nuclear Transfer-Generated Stem Cells for Transplantation Having Homozygous MHC Alleles, and Methods for Making and Using Such a Stem Cell Bank

09/736,268 Transfer to De-Differentiate Recipient Cells

Field of Use
Field shall mean (1) the research, development, manufacture and selling of human and non-human animal cells for commercial research use, including small molecule and other drug testing and basic research and (2) the manufacture and selling of human cells for therapeutic and diagnostic use in the treatment of human (a) diabetes and (b) liver diseases; but Field shall exclude applications involving the use of cells in the treatment of tumors where the primary use of the cells is the destruction or reduction of tumors and does not involve regeneration of tissue or organ function.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.